2025
Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]).
Nader Marta G, Ameye L, Viale G, Martins-Branco D, Paesmans M, Aftimos P, Desmedt C, Choudhury A, Wolff A, Krop I, Piccart-Gebhart M, de Azambuja E. Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). Journal Of Clinical Oncology 2025, 43: 542-542. DOI: 10.1200/jco.2025.43.16_suppl.542.Peer-Reviewed Original ResearchTime to distant recurrenceInvasive lobular carcinomaNo special typeDisease-free survivalCentral nervous system recurrenceCentral pathology reviewTrastuzumab-containing armsCentral nervous systemOutcomes of patientsLong-term outcomesOverall survivalHistological subtypesALTTO trialPathology reviewLobular carcinomaBreast cancerHistological subtype of breast cancerLong-term outcomes of patientsIncidence of CNS metastasesRandomized phase III trialSubtypes of breast cancerProportion of invasive lobular carcinomasLocal pathologyHormone receptor-positivePattern of relapse
2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman D, Colleoni M, Roylance R, Kelly C, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard S, Wolff A, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang C, Baruch N, Bliss J, Ferro A, Gralow J, Kim S, Kroep J, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop A, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber R, Moreno-Aspitia A. Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]. ESMO Open 2024, 9: 103938. PMID: 39418883, PMCID: PMC11532431, DOI: 10.1016/j.esmoop.2024.103938.Peer-Reviewed Original ResearchDisease-free survivalHER2-positive early breast cancerEarly breast cancerOverall survivalALTTO trialBreast cancerFollow-upMetastatic HER2-positive breast cancerDual anti-HER2 blockadeAnti-human epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Lapatinib to trastuzumabAnti-HER2 therapyAnti-HER2 blockadeTreatment groupsOutcomes of patientsAdjuvant trastuzumabOpen-labelAdjuvant chemotherapyPrimary endpointSecondary endpointsEfficacy analysisMulticenter studyAnti-HER2
2022
139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
Rediti M, Venet D, Garcia A, Agbor-tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Liu M, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial. Annals Of Oncology 2022, 33: s602-s603. DOI: 10.1016/j.annonc.2022.07.174.Peer-Reviewed Original Research
2018
correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals Of Oncology 2018, 29: 2152. PMID: 29701764, PMCID: PMC6225898, DOI: 10.1093/annonc/mdx805.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply